| Revision as of 03:47, 23 December 2024 editBuidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,046 edits ←Created page with ''''Dorzagliatin''' is a glucokinase activator that is being developed to treat diabetes.<ref>{{cite journal |last1=Chow |first1=Elaine |last2=Wang |first2=Ke |last3=Lim |first3=Cadmon K.P. |last4=Tsoi |first4=Sandra T.F. |last5=Fan |first5=Baoqi |last6=Poon |first6=Emily |last7=Luk |first7=Andrea O.Y. |last8=Ma |first8=Ronald C.W. |last9=Ferrannini |first9=Ele |last10=Mari |first10=Andrea |last11=Chen |first11=Li |last12=Chan |first12=Juliana C.N. |titl...' | Latest revision as of 07:47, 30 December 2024 edit undoOAbot (talk | contribs)Bots440,440 editsm Open access bot: pmc updated in citation with #oabot. | ||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
| '''Dorzagliatin''' is a ] activator that is being developed to treat diabetes.<ref>{{cite journal |last1=Chow |first1=Elaine |last2=Wang |first2=Ke |last3=Lim |first3=Cadmon K.P. |last4=Tsoi |first4=Sandra T.F. |last5=Fan |first5=Baoqi |last6=Poon |first6=Emily |last7=Luk |first7=Andrea O.Y. |last8=Ma |first8=Ronald C.W. |last9=Ferrannini |first9=Ele |last10=Mari |first10=Andrea |last11=Chen |first11=Li |last12=Chan |first12=Juliana C.N. |title=Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes |journal=Diabetes |date=1 February 2023 |volume=72 |issue=2 |pages=299–308 |doi=10.2337/db22-0708}}</ref> Unlike other diabetes drugs, it is intended to increase insulin sensitivity.<ref>{{cite journal |last1=Zhu |first1=Dalong |last2=Li |first2=Xiaoying |last3=Ma |first3=Jianhua |last4=Zeng |first4=Jiao’e |last5=Gan |first5=Shenglian |last6=Dong |first6=Xiaolin |last7=Yang |first7=Jing |last8=Lin |first8=Xiaohong |last9=Cai |first9=Hanqing |last10=Song |first10=Weihong |last11=Li |first11=Xuefeng |last12=Zhang |first12=Keqin |last13=Zhang |first13=Qiu |last14=Lu |first14=Yibing |last15=Bu |first15=Ruifang |last16=Shao |first16=Huige |last17=Wang |first17=Guixia |last18=Yuan |first18=Guoyue |last19=Ran |first19=Xingwu |last20=Liao |first20=Lin |last21=Zhao |first21=Wenjuan |last22=Li |first22=Ping |last23=Sun |first23=Li |last24=Shi |first24=Lixin |last25=Jiang |first25=Zhaoshun |last26=Xue |first26=Yaoming |last27=Jiang |first27=Hongwei |last28=Li |first28=Quanmin |last29=Li |first29=Zongbao |last30=Fu |first30=Maoxiong |last31=Liang |first31=Zerong |last32=Guo |first32=Lian |last33=Liu |first33=Ming |last34=Xu |first34=Chun |last35=Li |first35=Wenhui |last36=Yu |first36=Xuefeng |last37=Qin |first37=Guijun |last38=Yang |first38=Zhou |last39=Su |first39=Benli |last40=Zeng |first40=Longyi |last41=Geng |first41=Houfa |last42=Shi |first42=Yongquan |last43=Zhao |first43=Yu |last44=Zhang |first44=Yi |last45=Yang |first45=Wenying |last46=Chen |first46=Li |title=Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial |journal=Nature Medicine |date=May 2022 |volume=28 |issue=5 |pages=965–973 |url=https://www.nature.com/articles/s41591-022-01802-6}}</ref> | '''Dorzagliatin''' is a ] activator that is being developed to treat diabetes.<ref>{{cite journal |last1=Chow |first1=Elaine |last2=Wang |first2=Ke |last3=Lim |first3=Cadmon K.P. |last4=Tsoi |first4=Sandra T.F. |last5=Fan |first5=Baoqi |last6=Poon |first6=Emily |last7=Luk |first7=Andrea O.Y. |last8=Ma |first8=Ronald C.W. |last9=Ferrannini |first9=Ele |last10=Mari |first10=Andrea |last11=Chen |first11=Li |last12=Chan |first12=Juliana C.N. |title=Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes |journal=Diabetes |date=1 February 2023 |volume=72 |issue=2 |pages=299–308 |doi=10.2337/db22-0708|pmc=9871194 }}</ref> Unlike other diabetes drugs, it is intended to increase insulin sensitivity.<ref>{{cite journal |last1=Zhu |first1=Dalong |last2=Li |first2=Xiaoying |last3=Ma |first3=Jianhua |last4=Zeng |first4=Jiao’e |last5=Gan |first5=Shenglian |last6=Dong |first6=Xiaolin |last7=Yang |first7=Jing |last8=Lin |first8=Xiaohong |last9=Cai |first9=Hanqing |last10=Song |first10=Weihong |last11=Li |first11=Xuefeng |last12=Zhang |first12=Keqin |last13=Zhang |first13=Qiu |last14=Lu |first14=Yibing |last15=Bu |first15=Ruifang |last16=Shao |first16=Huige |last17=Wang |first17=Guixia |last18=Yuan |first18=Guoyue |last19=Ran |first19=Xingwu |last20=Liao |first20=Lin |last21=Zhao |first21=Wenjuan |last22=Li |first22=Ping |last23=Sun |first23=Li |last24=Shi |first24=Lixin |last25=Jiang |first25=Zhaoshun |last26=Xue |first26=Yaoming |last27=Jiang |first27=Hongwei |last28=Li |first28=Quanmin |last29=Li |first29=Zongbao |last30=Fu |first30=Maoxiong |last31=Liang |first31=Zerong |last32=Guo |first32=Lian |last33=Liu |first33=Ming |last34=Xu |first34=Chun |last35=Li |first35=Wenhui |last36=Yu |first36=Xuefeng |last37=Qin |first37=Guijun |last38=Yang |first38=Zhou |last39=Su |first39=Benli |last40=Zeng |first40=Longyi |last41=Geng |first41=Houfa |last42=Shi |first42=Yongquan |last43=Zhao |first43=Yu |last44=Zhang |first44=Yi |last45=Yang |first45=Wenying |last46=Chen |first46=Li |title=Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial |journal=Nature Medicine |date=May 2022 |volume=28 |issue=5 |pages=965–973 |url=https://www.nature.com/articles/s41591-022-01802-6}}</ref> | ||
| ==References== | ==References== | ||
| {{reflist}} | {{reflist}} | ||
| ] | |||
Latest revision as of 07:47, 30 December 2024
Dorzagliatin is a glucokinase activator that is being developed to treat diabetes. Unlike other diabetes drugs, it is intended to increase insulin sensitivity.
References
- Chow, Elaine; Wang, Ke; Lim, Cadmon K.P.; Tsoi, Sandra T.F.; Fan, Baoqi; Poon, Emily; Luk, Andrea O.Y.; Ma, Ronald C.W.; Ferrannini, Ele; Mari, Andrea; Chen, Li; Chan, Juliana C.N. (1 February 2023). "Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes". Diabetes. 72 (2): 299–308. doi:10.2337/db22-0708. PMC 9871194.
- Zhu, Dalong; Li, Xiaoying; Ma, Jianhua; Zeng, Jiao’e; Gan, Shenglian; Dong, Xiaolin; Yang, Jing; Lin, Xiaohong; Cai, Hanqing; Song, Weihong; Li, Xuefeng; Zhang, Keqin; Zhang, Qiu; Lu, Yibing; Bu, Ruifang; Shao, Huige; Wang, Guixia; Yuan, Guoyue; Ran, Xingwu; Liao, Lin; Zhao, Wenjuan; Li, Ping; Sun, Li; Shi, Lixin; Jiang, Zhaoshun; Xue, Yaoming; Jiang, Hongwei; Li, Quanmin; Li, Zongbao; Fu, Maoxiong; Liang, Zerong; Guo, Lian; Liu, Ming; Xu, Chun; Li, Wenhui; Yu, Xuefeng; Qin, Guijun; Yang, Zhou; Su, Benli; Zeng, Longyi; Geng, Houfa; Shi, Yongquan; Zhao, Yu; Zhang, Yi; Yang, Wenying; Chen, Li (May 2022). "Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial". Nature Medicine. 28 (5): 965–973.